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Abstract 
 
The objective was to investigate whether myocardial adenosine triphosphate-sensitive K
+
 (KATP) channels open 
during the first 10min of regional ischaemia in Langendorff-perfused rat hearts. Changes in monophasic action 
potentials and arrhythmias were studied during myocardial ischaemia in both the presence and absence of 
pharmacological KATP modulation. Ligation of the left main coronary artery for 10min did not shorten the 
action potential duration (APD). The APD50 and APD80 (15.5±1.0 and 38.1±2.3ms, respectively [mean±S.E., 
n=15 hearts], immediately prior to ligation) increased transiently during the first 4min of ligation (by 160 and 
79% respectively, P<0.05), before returning to pre-ligation values, but without a significant below-baseline-
shortening. The cardiac electrogram showed no accompanying ventricular tachyarrhythmia (VT). These results 
raised the possibility that the myocardial KATP channels had not opened during the ligation. The KATP opener 
Ro 31-6930 (0.5 and 5µM) shortened the APD50 and APD80 during coronary ligation, to significantly below 
both their control and pre-occlusion values (P<0.05), and caused a concentration-dependent increase in both 
the incidence and duration of VT during the ligation. Ro 31-6930 at 5µM also shortened APD50 and APD80 
even before ligation (by 50 and 62% respectively, P<0.05), and abolished the normal APD-lengthening seen 
during ischaemia. The KATP blocker glibenclamide (1µM) abolished both the APD-shortening and pro-
arrhythmic effects of the KATP opener, both before and during coronary ligation, yet when delivered on its own, 
at the same concentration which abolished the effects of KATP activation, it had no significant effect on the 
APD changes seen during the coronary ligation alone. These results suggest that, in Langendorff-perfused rat 
hearts in the absence of drugs, KATP channels do not open during early myocardial ischaemia. 
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Introduction 
 
 In cardiac myocytes the normal intracellular ATP concentration keeps adenosine triphosphate-sensitive K
+
 
(KATP) channels in a closed state, but ATP removal can open them (25). Under certain conditions, this 
increases cellular K
+
 efflux, with a profound alteration of normal cardiac electrical activity, such as shortening 
of the action potential duration (APD) (39). Shortening of the action potential caused by the KATP current 
(IKATP) may protect the ischaemic myocardium by reducing intracellular Ca
2+
 overload and by conserving 
intracellular stores of ATP. However, by concomitantly shortening the refractory period, any APD reduction 
would favour reentrant arrhythmias (6,15). It should be noted that the newly recognised mitochondrial KATP 
channel, mitoKATP (which may open more readily than sarcolemmal KATP) also may been involved in 
myocardial protection, but this would not be expected to be reflected by changes in the APD (11). For reviews 
on the various electrical consequences of cardiac sarcolemmal KATP channel activation, see (2,24,39). 
 Several lines of evidence indicate that KATP channels can open within the first 5 to 10min of acute 
myocardial ischaemia, i.e.: before necrosis would be expected, but when lethal arrhythmias may occur. Thus, 
APD shortens within about 3min of ischaemia onset in several species, and is sensitive to KATP blockers in the 
intact hearts of dogs and rabbits (30). Additionally, KATP openers have been reported to cause, and KATP 
blockers to prevent, various ventricular arrhythmias during acute myocardial ischaemia in several species, 
including the rat (9,16). 
 However, ionic currents additional to IKATP are known to participate in APD-shortening during early 
ischaemia (4), and, there is evidence to suggest that KATP activation may not be the main cause of such APD-
shortening. For example, the reversal of APD-shortening in rabbits by the KATP blocker glibenclamide occurs 
well after 10min of ischaemia or hypoxia have elapsed (1,29), even though APD-shortening in this species 
occurs within 3min of ischaemia. Moreover, only partial reversal by glibenclamide of the APD-shortening 
effects of ischaemia or hypoxia have been observed (30). Indeed, KATP channels may not open at all under 
certain conditions. The intracellular ATP concentration remained in the millimolar range (perhaps as high as 
10mM) for the first 10min in some studies (18), yet half maximal inhibition of KATP channels in excised 
membrane patches is known to occur at 17-25µM (17), and so the possibility remains that significant KATP 
activation may not occur during early ischaemia, even when taking into account the limitations involved in 
comparing data obtained using different experimental techniques (24). 
Workman AJ et al. Do KATP channels open during ischaemia in the isolated rat heart? 
 
 
4 
 The rat has been used extensively to investigate the effects of pharmacological KATP modulators on 
arrhythmogenesis. In this species, an accumulation of K
+
 in the extracellular space has been detected after only 
15s of ischaemia, with [K
+
]o reaching 9mM after 5min. However, glibenclamide only partially altered this 
accumulation (with [K
+
]o still reaching 8mM after 5min) and exerted even less of an effect up to 25min beyond 
this time (38). This suggested only a limited involvement of KATP channels during early ischaemia in this 
species. Moreover, the APD has been shown to increase markedly during the first few minutes of ischaemia in 
the rat (26-28,40), i.e.: at a time when any KATP activation might have been expected to shorten APD. 
Furthermore, the APD was shown not to shorten at all during global ischaemia but to exhibit transient 
lengthening during the first 5min, followed by a second increase during the following 15min (26). An 
activation of only 1% of the available KATP conductance should be sufficient to shorten APD by approximately 
50% (24). We therefore hypothesised that KATP channels might not open during early ischaemia in this species. 
Ischaemic APD-lengthening (or a lack of APD-shortening) per se does not preclude concurrent KATP 
activation, and so data on the sensitivity of such changes to KATP blockers is required. There are currently no 
reports of investigations into the effects of KATP blockers on APD during ischaemia in intact rat hearts. 
 The aim of the present study, therefore, was to investigate whether KATP channels open during the first 
10min of myocardial ischaemia in Langendorff-perfused rat hearts, by assessing the sensitivity to 
pharmacologic KATP modulation, of changes in action potentials and arrhythmias during regional ischaemia in 
these intact hearts. 
 
 
Methods 
 
Isolation and perfusion of rat hearts in-vitro 
 The investigation conforms with the Guidance on the Operation of the Animals (Scientific Procedures) 
Act 1986. In accordance with Schedule 1, male Sprague Dawley rats (350-650g) were killed by concussion, 
followed by exsanguination. The heart was surgically exposed and a silk suture (Type W593 Mersilk, Ethicon) 
was placed beneath the left main coronary artery. The aorta was then cannulated and the heart was rapidly 
excised and perfused in Langendorff mode at 35-37
o
C (inside a water-heated covered glass chamber) with a 
physiological salt solution containing (mM): NaCl (136.9), glucose (11.1), MgCl2 (1.0), NaH2PO4 (0.3), 
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NaHCO3 (11.9), CaCl2 (0.9) and KCl (5), pH 7.4. This solution was bubbled with 95% O2 plus 5% CO2 and 
pre-filtered using a 5µm filter (Isopore SM, Millipore). The duration between concussion and exsanguination, 
and the start of Langendorff perfusion, was approximately 2-3min. 
 
Drugs 
 A stock solution of the KATP opener Ro 31-6930 (Roche Research Centre) was dissolved in H2O, and was 
freshly prepared before each experiment. A stock solution of the KATP blocker glibenclamide (Sigma) 
dissolved in dimethyl sulphoxide was prepared weekly and stored at 4
o
C. These drugs were added to the 
physiological salt solution when required, prior to perfusing the hearts. Final concentrations of Ro 31-6930 
were 50nM-10µM. Glibenclamide was used at 1µM, with 0.002% dimethyl sulphoxide in the final perfusate. 
 
Electrical recording techniques  
 The cardiac electrogram (CEG) was recorded continuously using stainless steel wires inserted into the 
ventricular apex and the right atrium, respectively. Arrhythmias were monitored on a scroll-type storage 
oscilloscope (Cardiostore SEM 431, SE Labs), and categorised using the guidelines of the Lambeth 
Conventions (34). Ventricular tachycardia and ventricular fibrillation were combined as ventricular 
tachyarrhythmia (VT). The heart rate was calculated from the CEG each minute, by measuring the number of 
QRS complexes which occurred during a 20s interval. Action potentials were recorded, in separate groups of 
hearts, from the left ventricular epicardial wall, 4mm distal to the coronary ligature, using a custom made 
suction electrode (internal diameter 1mm, external diameter 1.3mm), evacuated to 200mm Hg below 
atmospheric pressure. Voltage signals were low-pass filtered at 5kHz, digitised and stored on the magnetic disc 
of a scroll-type oscilloscope (Windograph, Gould). 
 
Experimental protocols 
 Hearts were allowed to stabilise for 10min by perfusing with the physiological salt solution. Recording of 
either the CEG or epicardial action potentials was then started. Perfusion fluid was switched to one containing 
drugs, if required, and baseline recordings continued for another 15min. The coronary ligature was then closed 
around the left main coronary artery. Electrical recordings were continued throughout a 10min period of 
ligation. This interval was chosen since it is substantially longer than that reported to be required for 
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ischaemic-KATP opening in many animal species, and would therefore aid comparison with those studies, and 
yet it would not be sufficiently long to cause myocardial necrosis. Coronary flow rate was measured by timed 
collection of coronary effluent. At the end of each experiment, the zone of non-perfused muscle was delineated 
using the technique of reverse staining, with Patent Blue V 1240 (at 4g.l
-1
). This produced a distinct zone of 
dye-stained (non-perfused) muscle (risk zone), which invariably extended over approximately 50% of the total 
ventricular surface, demonstrating the success of the coronary artery occlusion, and confirming the limited 
involvement of coronary collaterals in this species. Dye-stained and non-stained ventricular muscle masses 
were separated with scissors, blotted dry and weighed. In a separate group of 10 hearts, the suction electrode 
was replaced by a thermistor probe (Wayne Kerr), to measure the epicardial temperature in the ischaemic zone 
prior to and during coronary ligation. 
 
Data analysis and statistics 
 APD measurements were excluded if the suction electrode was found to have not been located centrally in 
the non-perfused area of muscle. All values were expressed as means±standard error (S.E.). Incidences of 
arrhythmias were compared using a χ
2
 test (with Yate's Correction). All data on arrhythmia duration, coronary 
flow rate and APD were subjected to a variance ratio test. Data were then compared using either a Student's t 
test or a Mann Whitney test (for non-parametric analysis), as appropriate. P<0.05 was considered significant. 
 
 
Results 
 
Acute left ventricular regional ischaemia did not cause arrhythmias in isolated rat hearts 
 Ligation of the left main coronary artery for 10min was not accompanied by any episode of VT in 
Langendorff-perfused rat hearts (n=10), despite producing a distinct zone of non-perfused muscle in each 
heart. The incidence of VT was zero during the 10min period prior to coronary occlusion. Occlusion abruptly 
reduced the total coronary flow rate from 10.6±0.7 to 6.7±0.6ml.min
-1
.g
-1
 ventricular weight (P<0.05, n=10, 
perfusion pressure=100cm H20). The mean wet weight of the muscular zone at risk of ischaemia, as revealed 
by staining, was 0.67±0.03g, or 52% of the total ventricular weight (n=10). The heart rate was 237±14 
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beats.min
-1
 1 min before coronary occlusion. During occlusion, the heart rate fell progressively, and to 
significantly below the pre-occlusion value only after 10min, to 197±18 beats.min
-1
 (P<0.05). 
 
The action potential duration did not shorten during coronary artery occlusion 
 Representative action potentials recorded from the left ventricular epicardium are shown in Fig. 1., with 
the typical action potential configuration (short duration) seen prior to ischaemia in Fig. 1.(a). The time course 
of changes in left ventricular action potentials recorded during the 10min period of coronary occlusion from 
the area at risk of ischaemia can be seen from the recordings in Fig. 1.(c). The APD at both 50 and 80% 
repolarisation (APD50 and APD80, respectively) was measured at a high time resolution [e.g.: Fig. 1.(b)], and 
the mean time course of these changes was plotted graphically, as shown in the "control" curves of Fig. 2. 
Neither APD50, nor APD80 shortened during occlusion. Rather, there was a transient (3-4min) increase in left 
ventricular APD at both measured levels of repolarisation, followed by a return to the pre-occlusion state in the 
last 4 or 5min of occlusion, with no sign of a significant below baseline shortening of APD. Immediately prior 
to the occlusion, APD50 and APD80 values were 15.5±1.0 and 38.1±2.3ms, respectively (n=15 hearts). After 
only 1min of occlusion, these had increased significantly, by 160 and 79%, respectively (P<0.05, n=15), 
before returning to the pre-ischaemic state. The APD increase was not associated with any change in epicardial 
surface temperature. Prior to ischaemia, this was 37.3±0.2
o
C, and was not significantly different at the end of 
the period of ischaemia, at 36.6±0.2
o
C (n=10). Action potential amplitude and duration were measured during 
prolonged perfusion in the absence of coronary artery occlusion in other hearts. At the start of the experiment, 
APD80 and action potential amplitude were 37.6±3.3ms and 12.3±1.8mV, respectively. After 45min of 
continuous perfusion, these values were not significantly different, at 34.1±3.6ms and 9.6±2.1mV, 
respectively. This demonstrates the substantial stability of the recordings, despite the application of prolonged 
suction. 
  Insert Fig.1. 
A KATP blocker did not alter action potentials during a 10min coronary occlusion 
 The KATP blocker glibenclamide at a concentration of 1µM would be expected to have blocked open 
cardiac KATP channels, but it had no effect on the APD changes caused by 10min of coronary occlusion. This 
lack of effect of glibenclamide on both APD50 and APD80 is shown in Fig. 2. The control and drug-treatment 
experiments were performed contemporaneously. There was no significant difference in the APD50 or APD80 
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values between these two groups at any time point during occlusion. Glibenclamide exerted a vasoconstrictor 
action in preliminary experiments, so perfusion pressure was raised to 133cm H20 for recording action 
potentials in glibenclamide-treated hearts, but kept at 100cm H20 in control hearts. This equalised coronary 
flow rates in the two groups, so that any effects of glibenclamide on APD were unlikely to have been obscured 
by its vasoconstrictor action.  
  Insert Fig.2. 
A KATP opener caused VT during the coronary occlusion 
 The KATP opener Ro 31-6930 caused VT to occur during 10min of coronary artery occlusion, and its 
incidence and duration were increased in a concentration-dependent manner by this drug. This can be seen in 
Fig. 3., which shows the effects of Ro 31-6930 between 0.5 and 10µM. In each case, Ro 31-6930 was 
introduced into the perfusate 15min before the occlusion. VT only occurred to a significant extent (compared 
to controls) with high concentrations of Ro 31-6930, i.e.: 5 or 10µM (Fig. 3.). With Ro 31-6930 at 5µM, no 
VT was observed prior to coronary occlusion, but a significant proportion of hearts displayed VT after only 
4min of the occlusion. However, at 10µM, Ro 31-6930 caused significant VT even prior to coronary occlusion, 
with all hearts displaying continuous VT within 3min of the occlusion. In preliminary experiments, Ro 31-
6930 exerted a potent vasodilator action, even at 0.05µM. This effect was maximal at 0.5µM, causing an 
increase in the total coronary flow rate from 10.6±0.7 to 14.5±1.0ml.min
-1
.g
-1
 ventricular weight (P<0.05, 
n=10). The perfusion pressure was therefore lowered to 66cm H20 when recording the CEG from hearts 
treated with the KATP opener. This equalised the coronary flow rates between the control group and all the 
drug-treated groups. The effects of the KATP opener on APD were unlikely therefore to have been obscured by 
its vasodilator action. The heart rate in groups treated with Ro 31-6930 at 0.5 and 5µM was 225±20 and 
246±16 beats.min
-1
, respectively, 1 min before coronary occlusion. The heart rate did not differ significantly in 
either group, from that of the control group at any time point prior to or during the occlusion. 
 
Pro-arrhythmic effects of the KATP opener were glibenclamide-sensitive 
 Glibenclamide, at the low concentration of 1µM abolished the pro-arrhythmic effects of Ro 31-6930 at 
each concentration tested. This effect of glibenclamide is clearly illustrated in Fig. 3., which shows both the 
incidence and duration of VT during ischaemia in groups of hearts perfused with various combinations of Ro 
31-6930 and glibenclamide. Glibenclamide on its own (denoted in the histograms by 0µM Ro 31-6930 in 
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combination with 1µM glibenclamide) did not cause VT to a significant extent (compared to controls) either 
before or during coronary occlusion, but prevented the pro-arrhythmic effects of Ro 31-6930 both before and 
during the period of coronary occlusion, even when in combination with Ro 31-6930 at the high concentration 
of 10µM. The heart rate in those hearts treated with glibenclamide alone was 221±13 beats.min
-1
 prior to 
coronary occlusion, and did not differ significantly from that of the control group at any time point prior to, or 
during the occlusion. The perfusion pressure in these hearts was adjusted in the same way as with the action 
potential recording experiments above. 
  Insert Fig.3. 
A KATP opener shortened action potentials during coronary occlusion 
 During a 10min coronary artery occlusion, the KATP opener Ro 31-6930 caused a concentration-dependent 
shortening of action potentials recorded from the area at risk of ischaemia. Fig. 4. shows the time course of the 
effects of a low concentration of Ro 31-6930 (0.5µM), on these left ventricular action potentials. This drug had 
no significant effect on either APD50 or APD80 prior to coronary occlusion, but it significantly shortened 
APD80 below the corresponding control values at each time point during the period of occlusion, and APD50 
values at most time points studied (n=13 hearts, 7-13 action potentials, P<0.05). This effect of the KATP opener 
became evident after only 1min of coronary occlusion (Fig. 4.). Beyond 4min of coronary occlusion, Ro 31-
6930 also shortened APD80 values below the pre-occlusion values at each time point (P<0.05). This contrasts 
markedly with the situation in the absence of the KATP opener. 
  Insert Fig.4. 
Fig. 5. shows the effects of a high concentration of Ro 31-6930 (5µM), administered under similar conditions. 
During coronary occlusion, Ro 31-6930 at 5µM markedly shortened both APD50 and APD80 at each time point, 
compared to the corresponding control values [Fig. 5.(a)], and in this case, the drug abolished the transient 
APD-lengthening that was seen in the control group. As at the lower concentration (0.5µM), Ro 31-6930 at 
5µM also significantly shortened action potentials below the pre-occlusion value seen during coronary 
occlusion (n=13, P<0.05). However, in contrast to the effects of the low concentration, the high concentration 
(5µM) of the KATP opener caused significant APD-shortening even before the occlusion, by 50 and 62%, for 
APD50 and APD80, respectively (n=13, P<0.05). Again, none of these electrical effects of the KATP opener 
were likely to have been complicated by its vasodilator action, since the coronary flow rates were adjusted to 
not be significantly different in control and drug-treated groups. Fig. 6. summarises these concentration-
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dependent effects of Ro 31-6930 in the two experimental phases. Significant shortening of APD prior to 
ischaemia only occurred with the KATP opener at high concentration, but the shortening of APD during 
ischaemia occurred at both 0.5 and 5µM. When APD80 shortened to much below 10ms, i.e.: during coronary 
occlusion in hearts treated with 5µM Ro 31-6930, paroxysms of VT became evident in the action potential 
recordings. After 5min of occlusion, it became impossible to measure APD due to continuous VT [Fig. 5.(b)]. 
This pro-arrhythmic effect of Ro 31-6930 at 5µM, and its association with a severely shortened APD80 are 
shown in Figs. 3. and 6. 
  Insert Fig 5. 
Action potential shortening by the KATP opener was glibenclamide-sensitive 
 The KATP blocker glibenclamide abolished the effects on APD50 and APD80, of both concentrations of the 
KATP opener Ro 31-6930, not only before, but also during coronary artery occlusion. Fig. 7.(a) shows that 
glibenclamide at the low concentration of 1µM completely prevented the shortening of APD80 that was caused 
by Ro 31-6930 at 0.5µM during the period of coronary occlusion (compare this with Fig. 4.). The complete 
reversal by 1µM glibenclamide of Ro 31-6930-induced APD-shortening was evident even when using 5µM Ro 
31-6930 [Fig. 7.(b) compared with Fig. 5.(a)]. This reversal by glibenclamide of the effects of Ro 31-6930 on 
APD during coronary occlusion, i.e.: a restoration of the normal APD, is consistent with the prevention by 
glibenclamide of the pro-arrhythmic effects of the KATP opener seen in Fig. 3, and confirms the involvement of 
KATP activation in both of these effects. 
 
 
Discussion 
 
 We have provided evidence to suggest that KATP channels do not open during the first 10min of 
myocardial regional ischaemia in Langendorff-perfused rat hearts. In agreement with several previous studies 
on rat isolated hearts (26-28,40), ischaemia did not shorten the action potential duration, thus raising the 
possibility that the KATP channels hadn't opened early on during the coronary artery occlusion. Our data 
obtained with pharmacologic KATP modulation supports this possibility, since the opening of KATP channels 
was able to cause marked APD-shortening during ischaemia [clearly detectable despite the normal (26-28,40) 
APD-lengthening seen in the absence of a drug], yet glibenclamide, which was able to completely abolish that 
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effect of the KATP opener (even after 10min of ischaemia) had no significant effect on the APD during that 
time, when it was delivered alone, and at the same concentration. 
 We used as an index of KATP activity, the sensitivity of the monophasic action potential (MAP) duration to 
pharmacologic KATP modulation, not, importantly, the ischaemic APD-change per se. Direct measurement of 
IKATP (such as with voltage clamping of single channels) is unfeasible in the intact heart, and the latter model 
was used to study the electrical consequences of "true" myocardial ischaemia [as opposed to "simulated" 
ischaemia, which inevitably must be utilised when measuring single channel currents directly (37)]. The 
repolarisation time course of the MAP, such as that recorded using a suction electrode, accurately reproduces 
that of the action potential recorded with microelectrodes from the same region (14), and the constancy of our 
suction electrode recordings over a 45min experimental period demonstrates the reliability of the method in 
our model. 
  Insert Fig.6. 
 The time-course of the ischaemia-induced APD changes, namely, marked and transient lengthening, 
closely followed the reported transmembrane APD changes in rat isolated hearts during 25min of global low-
flow ischaemia (26). The cause of the early transient APD increase is unknown. Mechanical changes, a fall in 
either temperature or intracellular pH, and the release of catecholamines has each been suggested (7), as well 
as blockade of both the inward rectifier (IK1) (13,35) and transient outward (ITO) (33) K
+
 currents. It should be 
noted that such marked APD-prolongation is largely species-specific: in mammals larger than the rat, early 
ischaemic APD change is characterised mainly by prominent shortening. In the study of Henry et al (13), rat 
isolated ventricular myocytes were used, so coronary artery mechanical deflation was therefore absent, yet a 
similar transient APD-lengthening was demonstrated during simulated ischaemia. Moreover, it is important to 
note that a fall in temperature did not occur in the present study. Catecholamine release could only have been 
local (as opposed to systemic) in the present, in-vitro, model, and local release is known to be negligible during 
the first 10-15min of ischaemia (4). In the absence of the much larger, second phase accumulation of 
catecholamines which occurs in-vivo after 15min of ischaemia, catecholamine release would not have 
substantially influenced APD during ischaemia in the present experiments, which is consistent with the 
absence of heart rate increase during ischaemia. In contrast, acute blockade of ITO (a major repolarising current 
in the rat ventricle) is a more likely candidate for the APD-prolongation (33), and such an ionic mechanism is 
consistent with a significant prolongation of the APD by 4-aminopyridine in this model (40) and could account 
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for a suppression of phase 1 repolarisation during ischaemia (Fig. 1c). Since the APD-lengthening during early 
ischaemia was abolished by the KATP opener Ro 31-6930 and this effect was glibenclamide-sensitive, this 
suggests that any non-IKATP-induced changes that might tend to increase APD were unable to mask any 
concurrent effect of KATP opening on APD. 
 In the present study, the KATP opener Ro 31-6930 caused action potential shortening and VT during the 
10min period of coronary occlusion, each in a concentration-dependent manner. Ro 31-6930 is related to the 
benzopyran KATP opener cromakalim, but has a non-chiral structure of much higher biological potency (8). Its 
KATP opening activity has previously been demonstrated in several experimental models (3,10,12), including 
cardiac tissue, in which 3µM Ro 31-6930 caused action potential shortening, which was reversed both by ATP 
(100µM) and glibenclamide (0.3-3µM) (3). It is noteworthy that we report a greater decrease in APD by 
0.5µM Ro 31-6930 during early ischaemia, than prior to ischaemia. It has been shown previously that an 
increase in intracellular [ADP] reduced the sensitivity of KATP channels to block by ATP (17). Therefore, it 
might be speculated that such a biochemical event (or other, e.g.: an increased intracellular acidosis or 
accumulation of adenosine) might sensitise KATP to an opening action of Ro 31-6930, possibly as a result of 
reduced inhibitory effect of ATP on the KATP channel. The significant pro-arrhythmic effect of Ro 31-6930 
during ischaemia is consistent with a pro-arrhythmic effect from cromakalim-induced KATP activation, seen in 
a previous study during a 10min period of occlusion in rat working hearts (9). The Ro 31-6930-induced VT 
that we observed even prior to ischaemia has also been seen by other workers with related drugs (6). Other 
studies on intact hearts have revealed significant KATP opener-induced arrhythmogenesis and a shortening of 
the QT interval (36) and refractory periods (1) during ischaemia. The implications of this potentially 
undesirable property for the therapeutic use of this group of drugs warrants further study. 
  Insert Fig.7. 
 The KATP blocker glibenclamide, at the relatively low concentration of 1µM, completely reversed the 
APD-shortening and pro-arrhythmic effects of the KATP opener Ro 31-6930 seen during 10 min of coronary 
artery occlusion. This, as well as confirming that these effects of Ro 31-6930 were due to KATP activation, 
suggested that if KATP activation should occur in the absence of a KATP opening drug, it would be detectable as 
APD-shortening which would be glibenclamide-sensitive. The main supporting evidence that the KATP 
channels had not opened during the occlusion alone, therefore, was provided by using glibenclamide alone, 
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since at the same concentration (1µM) which abolished the APD-shortening effects of the KATP opener, 
glibenclamide had no effect on the action potentials during the occlusion. 
 Previously reported electrical effects of glibenclamide during ischaemia or hypoxia have been variable. 
Moritani et al (22) demonstrated a complete suppression of APD-shortening during a 5min coronary occlusion 
in dogs in-vivo. Some attenuation by glibenclamide of APD-shortening during ischaemia (5,30), hypoxia 
(20,29) and dinitrophenol-induced metabolic blockade has also been reported (23). Glibenclamide had no 
effect until 45min of hypoxia had occurred in the rabbit, however (29), but some attenuation of the refractory 
period shortening occurred in a similar model (1). In canine ventricular isolated tissues, glibenclamide also was 
unable to restore the loss of the action potential plateau induced by simulated ischaemia (19).  
 The lack of effect of glibenclamide on the APD in the present study, is consistent with a study by Wilde et 
al (38) who have demonstrated that, in rat isolated hearts, extracellular K
+
 accumulation (the earliest effect 
detected during ischaemia, and at least partly mediated by K
+
 channels) also was insensitive to glibenclamide 
during early ischaemia. 
 Glibenclamide, although not entirely selective for KATP channels, is nevertheless acknowledged as one of 
the best presently available KATP blockers. However, it is acknowledged that, in some studies, doubts have 
been raised concerning the efficacy of glibenclamide to block KATP channels during ischaemia or hypoxia. 
Venkatesh and colleagues have suggested that an accumulation of cytosolic ADP, such as occurs early during 
ischaemia (when [ADP] rises rapidly to the 100µM range), might limit the ability of glibenclamide (even at 
100µM) to block cellular K
+
 loss in guinea pig ventricular myocytes during metabolic blockade (32). Use of 
the non-sulphonylurea 5-hydroxydecanoate (5-HD) might be considered in future studies, although it has been 
shown previously (22) that no additional KATP blocking effect of 5-HD occurred during coronary occlusion in 
dogs, to that produced by pre-treatment with glibenclamide. It is noteworthy that 5-HD has been reported to be 
selective for mitoKATP (21), and its use, therefore, may not be appropriate for investigating sarcolemmal KATP 
channels. Nevertheless, a study of effects of 5-HD on the electrophysiological responses to Ro 31-6930 in this 
model might be considered. In the present study, we found that 10µM glibenclamide produced quantitatively 
similar results to 1µM, and owing to the complete antagonism of Ro 31-6930's effects with 1µM and the 
reduced risk of actions additional to IKATP blockade [such as block of cardiac ventricular A-kinase-dependent 
Cl
-
 current with >1µM glibenclamide (31)], we chose to do the majority of experiments with 1µM 
glibenclamide. The preservation of the KATP modulating drugs' effects was an important factor to consider in 
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our interpretation of the results, and in the present study, 1µM glibenclamide was able to entirely block effects 
of Ro 31-6930 on both APD and VT, during coronary occlusion, as well as before it, indicating its suitability 
to block KATP channels during ischaemia in the present model.  
 
Limitations of the study 
 The following should be considered when interpreting our findings. Firstly, it is unknown to what depth 
of tissue MAPs are recorded, since these are injury currents flowing from an area of uninjured tissue 
surrounding depolarised cells beneath the electrode. Therefore, the MAPs recorded from the ischaemic zone 
during coronary ligation inevitably contained a component from the surrounding, normally perfused zone. 
Such a component should not seriously limit interpretation of the data, however, since it seems not to have 
been large enough to prevent clear detection of APD-shortening in the ischaemic zone with low dose Ro 31-
6930, despite this concentration having been shown to have no effect on the APD in normally perfused muscle 
(and presumably, therefore, on non-ischaemic tissue during regional ischaemia). Secondly, it is unclear why 
1µM glibenclamide caused a small degree of APD-shortening prior to ischaemia. The only expected effect on 
APD of blockade of any open KATP channels prior to ischaemia, would be to prolong, not shorten it, and so we 
cannot exclude the possibility that effects additional to KATP blockade were operating, and that these might 
have had a similar effect on the APD during ischaemia. In comparison, however, the pronounced, and 1µM 
glibenclamide-sensitive APD-shortening effects of the KATP opener seen during ischaemia, lend support to our 
conclusion that KATP had largely remained closed during ischaemia in the absence of drugs. Thirdly, the use of 
an in-vitro preparation coupled with a relatively short period of ischaemia and relatively high perfusate [KCl], 
whilst permitting action potential recording, is known to result in fewer and less severe episodes of VT than 
would be encountered in-vivo with a longer ischaemic insult, and may be associated with a sub-physiological 
heart rate. Finally, the fact that in a rat heart performing no external work, no APD-shortening was observed 
during a 10min period of ischaemia [and none would be expected even during 30min in this model (26)], does 
not preclude KATP activation prior to this in hearts of other species, and in those performing external work, 
either in-vitro or in-vivo. The present results, therefore, may be both model-, and species-dependent. 
 In summary, whilst caution must be exercised in interpreting a complex situation in a specific 
experimental model, our data suggest that cardiac KATP channels did not open as a prominent feature during the 
first 10min of myocardial regional ischaemia in the Langendorff-perfused rat heart. 
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Figure legends 
 
Fig. 1. 
Suction electrode-recorded action potentials from the left ventricular epicardial wall. (a) Typical configuration 
of a baseline action potential recording. The APD50 and APD80 were 14 and 45ms, respectively). (b) Time 
resolution of APD measurement method. A recording of an action potential with a short duration (from a heart 
treated with the KATP opener Ro 31-6930 at 5µM) illustrates the high time resolution obtained and required for 
accurate measurement of the APD50 (6.1ms in this case). (c) Change in APD during early ischaemia. Values 
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beneath each trace (recorded from the same heart) indicate the time (min) relative to occlusion of the left main 
coronary artery. The APD50 and APD80 (13 and 37ms, respectively, for the pre-occlusion trace) increased 
transiently during the first minutes of occlusion, before returning to approximate baseline levels (APD50 and 
APD80 =15 and 35ms, respectively, after 10min). 
 
Fig. 2. 
Time course of APD changes during coronary occlusion, and lack of effect of a KATP blocker. Following a 
5min period of baseline recording, the left main coronary artery was occluded at time zero (indicated by 
vertical arrow), and recordings were taken continuously for a further 10min. Values (APD50 and APD80) are 
means (with error bars denoting S.E.); n=15 hearts (6-15 action potentials) in both control and glibenclamide-
treated groups. *'s denote a significant difference (P<0.05) from control values at each time point prior to and 
during coronary occlusion. 
 
Fig. 3. 
Reversal by glibenclamide of effects of a KATP opener on arrhythmias during coronary occlusion. Upper panel 
shows the incidence of ventricular tachyarrhythmias (VT) recorded during a 10min occlusion of the left main 
coronary artery. Lower panel shows the associated durations of VT. Values are means, with the S.E. of 
duration data indicated by error bars. NV=no value recorded, i.e.: zero. For groups of Ro 31-6930-treated 
hearts (n=7-10), *'s denote a significant difference (P<0.05) from the control value (i.e.: with Ro 31-6930 at 
0µM). Hearts treated with glibenclamide (n=9-10 per group): both the incidence and duration of VT in hearts 
treated with glibenclamide alone (indicated by 0µM Ro 31-6930 in combination with 1µM glibenclamide) 
were not significantly different from the control values of 0% and 0s, respectively. There were no significant 
differences in either the incidence or duration of VT, between any of the drug-combination-treated groups. 
 
Fig. 4. 
Effects of a low concentration of a KATP opener on APD changes during coronary occlusion. Upper panel 
shows changes in APD50 and lower panel, in APD80. Values are means (n=13 hearts, 7-13 action potentials), 
with error bars denoting S.E. In each heart, the left main coronary artery was occluded at time 0, indicated by 
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vertical arrow. *'s denote significant differences (P<0.05) from control values at each time point, prior to and 
during coronary occlusion.  
 
Fig. 5. 
Effects of a high concentration of a KATP opener on action potentials during coronary occlusion. (a) Effects of 
Ro 31-6930 (5µM) on APD. Values are means (n=13 hearts, 4-11 action potentials), with error bars denoting 
S.E. *'s denote significant differences (P<0.05) from control values at each time point, prior to and during 
coronary occlusion. APD could not be recorded beyond 4min of occlusion in hearts treated with Ro 31-6930 at 
5µM, due to the appearance of continuous VT. (i) and (ii) indicate times at which traces in (b) were recorded. 
(b) Left ventricular epicardial voltage signals, sampled from a heart treated with 5µM Ro 31-6930. (i) Trace 
showing the last action potential recorded during ischaemia (APD50 and APD80 =4 & 9ms, respectively) prior 
to interruption of APD measurement by VT, which eventually caused complete degeneration of the signal (ii). 
 
Fig. 6. 
Concentration-dependent effects of Ro 31-6930 on APD prior to and during coronary occlusion. Effects of Ro 
31-6930 on APD immediately prior to coronary occlusion (Pre-occlusion APD) are shown in comparison with 
the shortest mean APD recorded during the subsequent 10min occlusion. Values (APD80) are means; error bars 
denote S.E. *'s = significant differences from the control group (Ro 31-6930 at 0µM) within each experimental 
phase. §'s = significant differences from the pre-occlusion value, for a given concentration of Ro 31-6930. 
Thus, Ro 31-6930 only shortened APD prior to occlusion, when delivered at 5µM, but shortened APD below 
the pre-occlusion value during occlusion, when delivered at both 0.5 and 5µM. 
 
Fig. 7. 
The abolition by glibenclamide of Ro 31-6930-induced changes in APD. (a) Effect of Ro 31-6930 
(0.5µM)+glibenclamide (1µM). (b) Effect of Ro 31-6930 (5µM)+glibenclamide (1µM). Only changes in 
APD80 are shown. Values are means, with error bars denoting S.E. (n=15 hearts, 7-15 action potentials, for 
each control and drug combination-treated group). In each heart, the left main coronary artery was occluded at 
time zero, indicated on the time scales by the vertical arrows. Asterisks denote significant differences (P<0.05) 
from control values at each time point, prior to and during coronary occlusion. 
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Fig. 1. 
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Fig. 2. 
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Fig. 3. 
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Fig. 4. 
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Fig. 5. 
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Fig. 6. 
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Fig. 7. 
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